Wang Baimiao,HU Lanyawen,TAO Yingli, et al. Clinical observation of metformin combined with low-dose aspirin in the treatment of patients with recurrent abortion and insulin resistance[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2021, 51(8): 658-661.
Abstract：Objective: To observe the clinical efficacy of metformin combined with low-dose aspirin in the treatment of patients with recurrent abortion and insulin resistance. Methods: In this study, 90 patients with recurrent abortion and insulin resistance were randomly divided into three groups: basic intervention group,metformin group (basic intervention & metformin group), and observation group (basic intervention & metformin &low-dose aspirin group). After 3-month treatment, body mass index (BMI), homeostasis model insulin resistance index (HOMA-IR), plasminogen activator inhibitor (PAI-1), homocysteine (Hcy), fasting insulin (FINS) level and pregnancy rate within 6 months after treatment were evaluated and compared among the three groups. Results:Compared with indexes before treatment, BMI, HOMA-IR and FINS were decreased in the three groups after treatment, with statistical difference (P<0.05). There was significant difference between the observation group and the basic intervention group (P<0.05), but there was no statistical difference between the observation group and the metformin group (P>0.05). After treatment, serum PAI-1 level and Hcy level decreased in three groups,especially significant in the observation group, and compared with the metformin and basic intervention group,the difference was significant (P<0.05). The pregnancy rate of the observation group and the metformin group was significantly different from that of the basic intervention group within 6 months after treatment (P<0.05),but there was no significant difference between the two groups (P>0.05). Conclusion: Metformin combined with low-dose aspirin can improve insulin resistance, reduce serum PAI-1 and Hcy levels and improve clinical pregnancy rate in patients with recurrent abortion and insulin resistance, with fewer adverse reactions.
